Lupin Wants To Go Generic With Nexium; AstraZeneca Feels The Heartburn
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Challenging product patents and later reaching a settlement with innovator companies have emerged as a strong business model for Indian generic drug maker Lupin. After settling at least five patent cases over the last two years, Lupin has now taken on AstraZeneca claiming non-infringement of Nexium (esomeprazole) patents in the United States